Cerus (NASDAQ:CERS)‘s stock had its “buy” rating reiterated by stock analysts at Robert W. Baird in a report issued on Friday. They currently have a $5.00 price objective on the biotechnology company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 28.53% from the company’s previous close.

Several other equities research analysts have also recently commented on CERS. BidaskClub raised shares of Cerus from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. ValuEngine cut shares of Cerus from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut shares of Cerus from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Finally, Cowen set a $6.00 price target on shares of Cerus and gave the stock a “buy” rating in a research report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $6.17.

Shares of Cerus (CERS) traded down $0.06 during midday trading on Friday, hitting $3.89. 680,727 shares of the stock were exchanged, compared to its average volume of 984,317. Cerus has a 52 week low of $1.93 and a 52 week high of $5.36. The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The company had revenue of $10.80 million for the quarter, compared to analysts’ expectations of $11.95 million. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.14) earnings per share. equities analysts anticipate that Cerus will post -0.59 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Premier Asset Management LLC acquired a new position in shares of Cerus during the 3rd quarter worth about $348,000. Senvest Management LLC increased its stake in shares of Cerus by 0.7% during the 3rd quarter. Senvest Management LLC now owns 2,960,398 shares of the biotechnology company’s stock worth $8,082,000 after purchasing an additional 20,000 shares during the last quarter. Elk Creek Partners LLC increased its stake in shares of Cerus by 6.8% during the 3rd quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock worth $16,730,000 after purchasing an additional 388,741 shares during the last quarter. BB&T Securities LLC acquired a new position in Cerus in the 3rd quarter valued at about $100,000. Finally, Schwab Charles Investment Management Inc. grew its stake in Cerus by 6.0% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 401,735 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 22,753 shares during the last quarter. Institutional investors own 58.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/01/cerus-cers-given-buy-rating-at-robert-w-baird.html.

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.